{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:24:23Z","timestamp":1787772263919,"version":"build-2784847793"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      Vitiligo is an acquired chronic autoimmune skin disorder with an estimated prevalence of 1% worldwide. The CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell-mediated chemokines such as CXCR3, CXCL9 and CXCL10 are the non-specific action immunomodulators that are responsible for the depigmentation and progression in vitiligo.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to explore the expression levels of serum CXCL9-11 in vitiligo patients who received the transplantation of cultured autologous melanocytes (TCAMs) before and after the operation and correlate their expressions with clinical stage, subtype and course of the vitiligo disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      The expression levels of serum CXCL9-11 were measured in the peripheral blood of 26 progressive vitiligo patients, 24 stable vitiligo, 13 TCAM patients and 30 healthy control (HC) cases using enzyme-linked immunosorbent assay (ELISA). The potential correlations between their expressions and disease features such as stage, type and surgical treatment were evaluated using Student's\n                      <jats:italic toggle=\"yes\">t<\/jats:italic>\n                      -test.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The expression levels of serum CXCL9-11 increased by ~1.4, ~1.6 and ~2.3-fold in vitiligo patients compared with HCs (\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01). The expression levels of all chemokines were significantly higher in progressive vitiligo patients than in stable vitiligo (\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01). The increasing expression levels of serum CXCL9, CXCL10 and CXCL11 were significantly related to the different types of vitiligo patients (\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.05). Preoperative expression levels of serum CXCL9-11 were significantly higher than the post-operative expression levels (\n                      <jats:italic toggle=\"yes\">P &lt;<\/jats:italic>\n                      0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Our results demonstrate that increasing expression levels of the CXC family play a key role in the immunopathogenesis of vitiligo. The abnormal expression of the CXC family may be considered an effective and therapeutic target for TCAM treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_925_22","type":"journal-article","created":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T02:26:16Z","timestamp":1715739976000},"page":"486-491","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Transplantation of Cultured Autologous Melanocytes on CXCL9, CXCL10 and CXCL11 Expressions in Vitiligo"],"prefix":"10.4103","volume":"68","author":[{"given":"Chen","family":"Xu","sequence":"first","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixian","family":"Lei","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Wang","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"Hairuola","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Kang","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology and Venereology, People's Hospital of Xinjiang Uygur Autonomous Region, China"},{"name":"From the Xinjiang Clinical Research Center for Dermatologic Diseases, China"},{"name":"From the Xinjiang Key Laboratory of Dermatology Research, Urumqi, Xinjiang Uygur Autonomous Region, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240829","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","article-title":"Vitiligo","volume":"386","author":"Ezzedine","year":"2015","journal-title":"Lancet"},{"key":"R2-20240829","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.autrev.2015.12.006","article-title":"Vitiligo: Pathogenesis, clinical variant, s and treatment approaches","volume":"15","author":"Iannella","year":"2016","journal-title":"Autoimmun Rev"},{"key":"R3-20240829","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: The vitiligo global issues consensus conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"R4-20240829","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/pcmr.12561","article-title":"Repigmentation in vitiligo: Position paper of the vitiligo global issues consensus conference","volume":"30","author":"Gan","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"R5-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2016.10.048","article-title":"discoveries in the pathogenesis and classification of vitiligo","volume":"77","author":"Rodrigues","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R6-20240829","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/bjd.12166","article-title":"Autoimmune thyroid disease in vitiligo: Multivariate analysis indicates intricate pathomechanisms","volume":"168","author":"Gey","year":"2013","journal-title":"Br J Dermatol"},{"key":"R7-20240829","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cyto.2008.06.017","article-title":"Chemotaxis chemokine receptors and human disease","volume":"44","author":"Jin","year":"2008","journal-title":"Cytokine"},{"key":"R8-20240829","first-page":"343","article-title":"Interfering with the IFN-\u03b3\/CXCL10 pathway to develop new targeted treatments for vitiligo","volume":"3","author":"Rashighi","year":"2015","journal-title":"Ann Transl Med"},{"key":"R9-20240829","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.immuni.2015.02.009","article-title":"CXCR3 chemokine receptor enables local CD8 (+) T cell migration for the destruction of virus-infected cells","volume":"42","author":"Hickman","year":"2015","journal-title":"Immunity"},{"key":"R10-20240829","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"R11-20240829","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/bjd.14416","article-title":"Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo","volume":"174","author":"Wang","year":"2016","journal-title":"Br J Dermatol"},{"key":"R12-20240829","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jocd.12517","article-title":"Cytokine profile (IL-2IL-6IL-17IL-22 and TNF- \u03b1) in vitiligo-new insight into the pathogenesis of the disease","volume":"18","author":"Sushama","year":"2019","journal-title":"J Cosmet Dermatol"},{"key":"R13-20240829","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/ajd.12256","article-title":"Vitiligo treatment update","volume":"56","author":"Daniel","year":"2015","journal-title":"Australas J Dermatol"},{"key":"R14-20240829","first-page":"388","article-title":"Cultured epidermal melanocyte transplantation in vitiligo: A review article","volume":"48","author":"Zokaei","year":"2019","journal-title":"Iran J Public Health"},{"key":"R15-20240829","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.det.2016.11.014","article-title":"Vitiligo pathogenesis and emerging treatments","volume":"35","author":"Rashighi","year":"2017","journal-title":"Dermatol Clin"},{"key":"R16-20240829","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/ced.14435","article-title":"Vitiligo: An update on systemic treatments","volume":"46","author":"Searle","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"R17-20240829","doi-asserted-by":"crossref","first-page":"4413","DOI":"10.3390\/molecules25194413","article-title":"Computational study of c-x-c chemokine receptor (cxcr) 3 binding with its natural agonists chemokine (c-x-c motif) ligand (cxcl) 9, 10 and 11 and with synthetic antagonists: Insights of receptor activation towards drug design for vitiligo","volume":"25","author":"Aguilera-Dur\u00e1n","year":"2020","journal-title":"Molecules"},{"key":"R18-20240829","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2016.12.021","article-title":"Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity","volume":"76","author":"Strassner","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"R19-20240829","doi-asserted-by":"crossref","first-page":"dgz289","DOI":"10.1210\/clinem\/dgz289","article-title":"Th1 chemokines in autoimmune endocrine disorders","volume":"105","author":"Fallahi","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"R20-20240829","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41374-017-0013-4","article-title":"Disruption of CXCR3 function impede the development of Sj\u00f6gren's syndrome-like xerostomia in non-obese diabetic mice","volume":"98","author":"Zhou","year":"2018","journal-title":"Lab Invest"},{"key":"R21-20240829","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00005-015-0356-8","article-title":"the role of CXC chemokines in pulmonary fibrosis of systemic lupus erythematosus patients","volume":"63","author":"Nielepkowicz-Go\u017adzi\u0144ska","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"R22-20240829","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jcv.2014.08.020","article-title":"CXCL9, CXCL10 and CXCL11 polymorphisms are associated with sustained virologic response in HIV\/HCV-coinfected patients","volume":"61","author":"Pineda-Tenor","year":"2014","journal-title":"J Clin Virol"},{"key":"R23-20240829","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12967-019-02172-3","article-title":"The combination of CXCL9, CXCL10 and CXCL11 levels during primary HIV infection predicts HIV disease progression","volume":"17","author":"Yin","year":"2019","journal-title":"J Transl Med"},{"key":"R24-20240829","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1172\/JCI120358","article-title":"CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis","volume":"128","author":"Zohar","year":"2018","journal-title":"J Clin Invest"},{"key":"R25-20240829","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/pcmr.12559","article-title":"Differential expression of CXCL9, CXCL10, and IFN-\u03b3in vitiligo and alopecia areata patients","volume":"30","author":"Maouia","year":"2017","journal-title":"Pigment Cell Melanoma Res"},{"key":"R26-20240829","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/DER.0000000000000391","article-title":"Chemokine signaling in allergic contact dermatitis: Toward targeted therapies","volume":"29","author":"Smith","year":"2018","journal-title":"Dermatitis"},{"key":"R27-20240829","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1111\/pcmr.12667","article-title":"CXCL-10 and Interleukin-6 are reliable serum markers for vitiligo activity: A multicenter cross-sectional study","volume":"31","author":"Abdallah","year":"2018","journal-title":"Pigment Cell Melanoma Res"},{"key":"R28-20240829","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1124\/mol.116.105502","article-title":"CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways","volume":"90","author":"Berchiche","year":"2016","journal-title":"Mol Pharmacol"},{"key":"R29-20240829","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3389\/fendo.2020.00630","article-title":"Pancreatic alpha-cells contribute together with beta-cells to cxcl10 expression in type 1 diabetes","volume":"11","author":"Nigi","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R30-20240829","doi-asserted-by":"crossref","first-page":"142","DOI":"10.2174\/1570159X15666171109161140","article-title":"The role of CXCR3 in neurological diseases","volume":"17","author":"Zhou","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"R31-20240829","doi-asserted-by":"crossref","first-page":"550","DOI":"10.4049\/jimmunol.172.1.550","article-title":"IFN-inducible protein 10\/CXC chemokine ligand 10-independent induction of experimental autoimmune encephalomyelitis","volume":"172","author":"Klein","year":"2004","journal-title":"J Immunol"},{"key":"R32-20240829","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jid.2016.10.048","article-title":"CXCR3 depleting antibodies prevent and reverse vitiligo in mice","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"key":"R33-20240829","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/pcmr.12974","article-title":"Vitiligo: Translational research and effective therapeutic strategies","volume":"34","author":"Thakur","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"R34-20240829","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3892\/etm.2016.3949","article-title":"Detection of auto antibodies and transplantation of cultured autologous melanocytes for the treatment of vitiligo","volume":"13","author":"Mei-Cai","year":"2017","journal-title":"Exp Ther Med"},{"key":"R35-20240829","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1001\/jamadermatol.2015.0299","article-title":"Efficacy of autologous melanocyte transplantation on amniotic membrane in patients with stable leukoderma: A randomized clinical trial","volume":"151","author":"Redondo","year":"2015","journal-title":"JAMA Dermatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_925_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:34:57Z","timestamp":1787769297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.ijd_925_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_925_22","relation":{},"ISSN":["0019-5154","1998-3611"],"issn-type":[{"value":"0019-5154","type":"print"},{"value":"1998-3611","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2022-11-01","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}